Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients.

Authors:
Dr. Srdjan Nikolovski, MD
Dr. Srdjan Nikolovski, MD
Clinical Center Serbia, University Children's Hospital, School of Medicine University of Belgrade
Research Associate
Clinical Research
Belgrade, Serbia | Yugoslavia

Am J Hematol 2016 Oct 22;91(10):1014-9. Epub 2016 Jul 22.

Clinic for Hematology, Lymphoma Center, Clinical Centre Serbia, Belgrade.

Lymphoma patients are at increased risk of thromboembolic events but thromboprophylaxis in these patients is largely underused. We sought to develop and validate a simple model, based on individual clinical and laboratory patient characteristics that would designate lymphoma patients at risk for thromboembolic event. The study population included 1,820 lymphoma patients who were treated in the Lymphoma Departments at the Clinics of Hematology, Clinical Center of Serbia and Clinical Center Kragujevac. The model was developed using data from a derivation cohort (n = 1,236), and further assessed in the validation cohort (n = 584). Sixty-five patients (5.3%) in the derivation cohort and 34 (5.8%) patients in the validation cohort developed thromboembolic events. The variables independently associated with risk for thromboembolism were: previous venous and/or arterial events, mediastinal involvement, BMI>30 kg/m(2) , reduced mobility, extranodal localization, development of neutropenia and hemoglobin level < 100g/L. Based on the risk model score, the population was divided into the following risk categories: low (score 0-1), intermediate (score 2-3), and high (score >3). For patients classified at risk (intermediate and high-risk scores), the model produced negative predictive value of 98.5%, positive predictive value of 25.1%, sensitivity of 75.4%, and specificity of 87.5%. A high-risk score had positive predictive value of 65.2%. The diagnostic performance measures retained similar values in the validation cohort. Developed prognostic Thrombosis Lymphoma - ThroLy score is more specific for lymphoma patients than any other available score targeting thrombosis in cancer patients. Am. J. Hematol. 91:1014-1019, 2016. © 2016 Wiley Periodicals, Inc.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24466DOI Listing
October 2016
36 Reads
4 Citations
3.800 Impact Factor

Publication Analysis

Top Keywords

lymphoma patients
20
validation cohort
12
thromboembolic events
12
patients
10
cohort developed
8
risk thromboembolic
8
clinical center
8
positive predictive
8
derivation cohort
8
lymphoma
7
cohort
5
arterial events
4
reduced mobility
4
kg/m2 reduced
4
involvement bmi>30
4
mediastinal involvement
4
events mediastinal
4
bmi>30 kg/m2
4
mobility extranodal
4
hemoglobin level 3
4

Similar Publications